Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0 ng/ml at population screening

被引:12
作者
Kitagawa, Yasuhide [1 ]
Ueno, Satoru [1 ]
Izumi, Kouji [1 ]
Kadono, Yoshifumi [1 ]
Konaka, Hiroyuki [1 ]
Mizokami, Atsushi [1 ]
Namiki, Mikio [1 ]
机构
[1] Kanazawa Univ, Grad Sch Med Sci, Dept Integrat Canc Therapy & Urol, Kanazawa, Ishikawa 9208640, Japan
关键词
Prostate cancer; PSA; Free/total PSA ratio; Screening; Risk factor; JAPANESE POPULATION; ANTIGEN LEVEL; MORTALITY;
D O I
10.1007/s00432-013-1543-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to investigate the cumulative probability of prostate cancer detection according to free/total prostate-specific antigen (PSA) ratio in men with PSA levels of 2.1-10.0 ng/ml and also likelihood of detecting clinically insignificant prostate cancer in population-based screening. A total of 1,277 men aged between 55 and 69 years with total PSA (tPSA) levels of 2.1-10.0 ng/ml screened in population screening in Kanazawa city and underwent systematic transrectal ultrasonography-guided prostate biopsy between 2000 and 2011 were enrolled. The cumulative probability of prostate cancer detection in biopsy according to age, serum tPSA, and free-to-total PSA (f/t PSA) ratio was investigated. The clinicopathological features of screening-detected prostate cancer were also investigated. Of the 1,277 subjects in the study population, 320 (25.0 %) were diagnosed with prostate cancer during the observation period. The probabilities of prostate cancer detection at 3 years were 64.5, 41.2, 28.5, and 14.3 % for the men with f/t PSA ratio a parts per thousand currency sign0.08, 0.09-0.13, 0.14-0.22, and a parts per thousand yen0.23, respectively; the differences in probabilities of prostate cancer detection among men with different f/t PSA ratios were statistically significant. Among 320 patients, 84 (26.3 %) had favorable clinicopathological features that made them suitable for active surveillance. The f/t PSA ratio in unfavorable cancer patients was significantly lower that that in favorable cancer patients. The present study demonstrated that the f/t PSA ratio was a strong predictor of future cancer detection and unfavorable cancerous features in prostate biopsy in men with total PSA levels of 2.1-10.0 ng/ml at population screening.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 21 条
  • [1] Prostate cancer screening in the prostate, lung, colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings from the initial screening round of a randomized trial
    Andriole, GL
    Levin, DL
    Crawford, ED
    Gelmann, ER
    Pinsky, PF
    Chia, D
    Kramer, BS
    Reding, D
    Church, TR
    Grubb, RL
    Izmirlian, G
    Ragard, LR
    Clapp, JD
    Prorok, PC
    Gohagan, JK
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (06): : 433 - 438
  • [2] [Anonymous], 1997, TNM CLASSIFICATION M
  • [3] Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population
    Arcangeli, CG
    Humphrey, PA
    Smith, DS
    Harmon, TJ
    Shepherd, DL
    Keetch, DW
    Catalona, WJ
    [J]. UROLOGY, 1998, 51 (04) : 558 - 564
  • [4] Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio
    Aus, G
    Becker, C
    Franzén, S
    Lilja, H
    Lodding, P
    Hugosson, J
    [J]. EUROPEAN UROLOGY, 2004, 45 (02) : 160 - 165
  • [5] Recent trends in prostate cancer mortality show a continuous decrease in several countries
    Bouchardy, Christine
    Fioretta, Gerald
    Rapiti, Elisabetta
    Verkooijen, Helena Maria
    Rapin, Charles Henry
    Schmidlin, France
    Miralbell, Raymond
    Zanetti, Roberto
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (02) : 421 - 429
  • [6] Early Detection of Prostate Cancer: AUA Guideline
    Carter, H. Ballentine
    Albertsen, Peter C.
    Barry, Michael J.
    Etzioni, Ruth
    Freedland, Stephen J.
    Greene, Kirsten Lynn
    Holmberg, Lars
    Kantoff, Philip
    Konety, Badrinath R.
    Murad, Mohammad Hassan
    Penson, David F.
    Zietman, Anthony L.
    [J]. JOURNAL OF UROLOGY, 2013, 190 (02) : 419 - 426
  • [7] MEASUREMENT OF PROSTATE-SPECIFIC ANTIGEN IN SERUM AS A SCREENING-TEST FOR PROSTATE-CANCER
    CATALONA, WJ
    SMITH, DS
    RATLIFF, TL
    DODDS, KM
    COPLEN, DE
    YUAN, JJJ
    PETROS, JA
    ANDRIOLE, GL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (17) : 1156 - 1161
  • [8] Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone
    Crawford, E. David
    Moul, Judd W.
    Rove, Kyle O.
    Pettaway, Curtis A.
    Lamerato, Lois E.
    Hughes, Alexa
    [J]. BJU INTERNATIONAL, 2011, 108 (11) : 1743 - 1749
  • [9] Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 μg per liter
    Finne, Patrik
    Auvinen, Anssi
    Maattanen, Liisa
    Tammela, Teuvo L.
    Ruutu, Mirja
    Juusela, Harri
    Martikainen, Paula
    Hakama, Matti
    Stenman, Ulf-Hakan
    [J]. EUROPEAN UROLOGY, 2008, 54 (02) : 362 - 370
  • [10] The Outcome of Prostate Cancer Screening in a Normal Japanese Population with PSA of 2-4 ng/ml and the Free/Total PSA Under 12%
    Ishidoya, Shigeto
    Ito, Akihiro
    Orikasa, Kazuhiko
    Kawamura, Sadafumi
    Tochigi, Tatsuo
    Kuwahara, Masaaki
    Yamanobe, Takuya
    Tomita, Yoshihiko
    Masumori, Naoya
    Tsukamoto, Taiji
    Shibuya, Daisuke
    Arai, Yoichi
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (12) : 844 - 848